Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sarepta Therapeutics Inc (NASDAQ:SRPT)

24.66
Delayed Data
As of 3:59pm ET
 +0.04 / +0.16%
Today’s Change
8.00
Today|||52-Week Range
41.97
-36.08%
Year-to-Date
3 Stocks Wall Street Hates
Jul 26 / MotleyFool.com - Paid Partner Content
Sarepta (SRPT) Posts Y/Y Wider Q2 Loss, Eteplirsen in Focus
Jul 20 / Zacks.com - Paid Partner Content
Why Investors Flocked to Sarepta Therapeutics Last Week
Jul 21 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close24.62
Today’s open24.62
Day’s range24.25 - 25.12
Volume1,497,659
Average volume (3 months)6,152,731
Market cap$1.2B
Dividend yield--
Data as of 3:59pm ET, 07/28/2016

Growth & Valuation

Earnings growth (last year)-53.39%
Earnings growth (this year)+5.03%
Earnings growth (next 5 years)+0.37%
Revenue growth (last year)-87.16%
P/E ratioNM
Price/Sales1,302.11
Price/Book5.90

Competitors

 Today’s
change
Today’s
% change
DERMDermira Inc-1.22-3.55%
LCILannett Company Inc-0.19-0.61%
ACHNAchillion Pharmaceut...-0.13-1.55%
TBPHTheravance Biopharma...+0.28+1.16%
Data as of 4:01pm ET, 07/28/2016

Financials

Last reporting dateJuly 19, 2016
EPS forecast (this quarter)-$1.23
Annual revenue (last year)$1.3M
Annual profit (last year)-$220.0M
Net profit margin-17,560.26%

Profile

Sector
Health Technology
Industry
Biotechnology
Senior VP, Chief Executive &
Medical Officer
Edward M. Kaye
Head-Operations &
Vice President
Gavin T. Malenfant
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Partner Offers

Search for Jobs